We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

330 hedge funds and large institutions have $9.13B invested in Acceleron Pharma in 2021 Q3 according to their latest regulatory filings, with 96 funds opening new positions, 86 increasing their positions, 105 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more call options, than puts

Call options by funds: $578M | Put options by funds: $195M

174% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 35

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

36% more capital invested

Capital invested by funds: $6.72B → $9.13B (+$2.41B)

22% more funds holding

Funds holding: 271 → 330 (+59)

18% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 105

Holders
330
Holders Change
+59
Holders Change %
+21.77%
% of All Funds
5.78%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.23%
New
96
Increased
86
Reduced
105
Closed
35
Calls
$578M
Puts
$195M
Net Calls
+$383M
Net Calls Change
+$402M

Top Buyers

Rank Fund Capital Flow
1
PCM
Pentwater Capital Management
Florida
+$137M
2
ACA
Avoro Capital Advisors
New York
+$131M
3
MF
Magnetar Financial
Illinois
+$109M
4
VI
Versor Investments
New York
+$52.5M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$46.8M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$132M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$95.6M
3
Ameriprise
Ameriprise
Minnesota
-$70.2M
4
Artisan Partners
Artisan Partners
Wisconsin
-$68.8M
5
BlackRock
BlackRock
New York
-$56.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SMC
151
S. Muoio & Co
New York
$2.58M +$1.96M +15,000 New
ASRS
152
Arizona State Retirement System
Arizona
$2.56M +$8.89K +68 +0.5%
PAMS
153
Pictet Asset Management (Switzerland)
Switzerland
$2.54M +$1.93M +14,765 New
ProShare Advisors
154
ProShare Advisors
Maryland
$2.46M +$192K +1,470 +11%
HA
155
Havens Advisors
New York
$2.41M +$1.83M +14,000 New
PIM
156
Platinum Investment Management
Australia
$2.39M – – –
Squarepoint
157
Squarepoint
New York
$2.27M +$1.5M +11,451 +657%
FCM
158
Frontier Capital Management
Massachusetts
$2.24M -$5.14M -39,264 -75%
KAS
159
Kestra Advisory Services
Texas
$2.18M -$15.4K -118 -0.9%
JRP
160
Jasper Ridge Partners
California
$2.15M – – –
Marshall Wace
161
Marshall Wace
United Kingdom
$2.08M +$1.58M +12,096 New
AAM
162
Advisors Asset Management
Colorado
$2.08M +$61.6K +471 +4%
BPA
163
Beacon Pointe Advisors
California
$2.02M +$726K +5,554 +89%
RJA
164
Raymond James & Associates
Florida
$1.95M -$151K -1,153 -9%
SG Americas Securities
165
SG Americas Securities
New York
$1.88M -$795K -6,077 -36%
BC
166
Birchview Capital
Vermont
$1.84M -$1.05M -8,000 -43%
BCI
167
Brinker Capital Investments
Pennsylvania
$1.79M – – –
TAL
168
TIG Advisors LLC
New York
$1.72M +$1.31M +10,003 New
NSEDCP
169
NJ State Employees Deferred Compensation Plan
New Jersey
$1.72M – – –
CC
170
Centiva Capital
New York
$1.72M +$822K +6,285 +169%
MCM
171
Mason Capital Management
New York
$1.72M +$1.31M +10,000 New
AGM
172
Alpine Global Management
New York
$1.69M +$1.29M +9,846 New
HS
173
HighVista Strategies
Massachusetts
$1.68M +$471K +3,600 +58%
AB
174
Amalgamated Bank
New York
$1.64M -$76K -581 -6%
AP
175
AtonRa Partners
Switzerland
$1.64M +$96.9K +741 +8%
5 6
7
8 9

XLRN Hedge Fund Activity: Q3 2021 in Review

330 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q3 2021, worth a combined $9.13B — up 36% from $6.72B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new XLRN positions and 35 closed out — a net gain of 61 holders — while 86 added to existing stakes and 105 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $137M. The largest seller was Wellington Management Group, cutting an estimated $132M.

  • 330 institutional investors held Acceleron Pharma (XLRN) as of Q3 2021, up from 271 in Q2 2021.
  • Funds reported $9.13B of Acceleron Pharma stock for Q3 2021, up 36% quarter-over-quarter.
  • 96 funds opened new Acceleron Pharma positions in Q3 2021 and 35 closed out, a net change of +61 holders.
  • The largest Acceleron Pharma buyer in Q3 2021 was Pentwater Capital Management, an estimated $137M added.
  • The largest Acceleron Pharma seller in Q3 2021 was Wellington Management Group, an estimated $132M sold.

Based on aggregated 13F filings for Q3 2021.